Home » Healthcare » Pharmaceuticals » Levothyroxine Sodium Market

Levothyroxine Sodium Market By Disease Indication (Hypothyroidism, Goiter, Thyroid Cancer, Myxedema Coma) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Industry Outlook

Hypothyroidism as a syndrome was first recognized in the 1870s, and its treatment with animal-extracted thyroid was achieved in the 1890s. Since 1927, synthetic thyroid hormone replacement therapy has been available, and in recent years, there has been a minor shift in treatment away from levothyroxine. The use of liothyronine T3 as monotherapy or in combination with levothyroxine T3/T4 is currently a popular treatment option. The current T3/T4 formulation, however, does not completely replicate the natural hormone pattern released by the human thyroid. Therefore, levothyroxine formulations have been widely available across the global market.

Treating hypothyroidism or underactive thyroid disease remains the single largest application of levothyroxine sodium. Treatment goals include correcting catabolic imbalances and reversing clinical progressions. According to the AACE (American Association of Clinical Endocrinologists), nearly 27 million people suffer from various thyroid disorders, most suffering from hypothyroidism—autoimmune thyroiditis and iodine deficiency being the most common causes. In the coming years, an increase in demand for levothyroxine to treat thyroid cancer may drive up sales of levothyroxine sodium products.

Levothyroxine sodium, sold under the brand name Synthroid, is a thyroid hormone approved by the Food and Drug Administration. The drug is considered to be as effective as branded versions of the same medication. In addition, the American Thyroid Association (ATA) has found no better alternatives than levothyroxine sodium; therefore, its guidelines confirm that levothyroxine sodium would remain the most preferred treatment choice for hypothyroidism. In addition, the ATA’s task force on thyroid replacement has recommended liothyronine combination therapy or thyroid extract therapy as an alternative to levothyroxine monotherapy, making these treatments less desirable than using levothyroxine alone.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Synopsis

Hypothyroidism to occupy the largest revenue share through the forecast period

Hypothyroidism is a common thyroid disorder observed worldwide. Autoimmune diseases (Hashimoto’s thyroiditis) and iodine deficiency account for the vast majority of primary hypothyroidism cases. Approximately one-third of the global population is housed in iodine-deficient areas, and the consequences of iodine deficiency often manifest through growth disorders and hypothyroidism. Hypothyroidism is ten times more prevalent in women than in men, whereas the prevalence of untreated overt hypothyroidism is significantly low. However, the implementation of new thyroid function testing and low threshold treatment indications for thyroid disorders has resulted in a growth in the number of prescriptions for levothyroxine for hypothyroidism. Overt hypothyroidism was found in 0.2% to 5.3% of people in Europe and 0.3% to 3.7% of people in the United States.

Asia-Pacific is on track to become a significant market for levothyroxine sodium.

North America remains the largest market for levothyroxine sodium drugs on the global front. The American Thyroid Association reports that approximately 12% of the U.S. population will develop thyroid conditions during their lifetime, and 20 million Americans have some form of thyroid condition at any given time. The high prevalence of thyroid disorders, better diagnostic regimens, and smaller treatment thresholds are the key factors supporting the global dominance of the North American market. Additionally, better reimbursements for levothyroxine drug regimens both for short- and long-term treatments drive the market’s growth. On the other hand, Asia Pacific will progress at a faster growth rate during the forecast period from 2018 to 2026. Rapidly growing awareness and significant untapped opportunities, along with an evidently large patient population, contribute to the rapid progress of the Asia-Pacific market. China and India are the most prominent markets for levothyroxine drugs. The prevalence of subclinical hypothyroidism in China has risen to 3.22%. A large cross-sectional multicity study in India reported a high prevalence of hypothyroidism (10%).

Periods of History and Forecast

This research report presents the analysis of each considered segment from 2016 to 2026, with 2017 as the base year for estimations. In addition, each segment’s compounded annual growth rates (CAGRs) are calculated for the forecast period from 2018 to 2026.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Scope by Segments

The levothyroxine sodium market report provides a quantitative assessment of the industry in terms of current and forecasted market size while also presenting the market dynamics. This market is segmented based on disease indications and geography.

In this report, the in-trend market dynamics of the global levothyroxine sodium industry are studied to reflect the qualitative and quantitative information pertaining to the industry. Factors such as drivers and challenges are studied in the report to determine the prevalent market trends. Opportunities for new and existing market players are also enumerated in this report. This study also includes profiling key market players in terms of their business overview, financial status, product offerings, and key developments. Some of the major players profiled in this report include Mylan Laboratories, Inc., Farmak (Farmak Group N.V.), Goldline Laboratories, Inc., IBSA Institut Biochimique SA, Fresenius Kabi USA Llc, Piramal Critical Care Ltd., Cediprof, Inc., King Pharmaceuticals Research And Development Llc, Abbvie, Inc., Takeda Pharmaceutical Company Ltd., Merck KGaA, Jerome, Stevens Pharmaceuticals, Inc., Pfizer, Inc., Teva Pharmaceuticals, Abbott Laboratories, Inc., Sandoz (Novartis International AG), and Lloyd, Inc.

Key questions are answered in this report.

What is the current and future status of the global levothyroxine sodium market in terms of market size?
At what CAGR will the global levothyroxine sodium market progress during the forecast period from 2018 to 2026?
What are the major market opportunities present in the market?
Which are the major drivers and restraints shaping the trends in the global levothyroxine sodium market?
Why is hypothyroidism the most common disease condition for levothyroxine sodium?
Will the rapidly progressing Asia-Pacific market challenge the prominence of North America?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global LS Market Portraiture
2.2. Global LS Market, by Disease Indication, 2017 (US$ Mn)
2.3. Global LS Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Levothyroxine Sodium (LS) Market: Dynamics and Future Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global LS Market, by Key Players, 2017

Chapter 4. Global Levothyroxine Sodium (LS) Market, by Disease Indication, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Hypothyroidism
4.3. Goiter
4.4. Thyroid Cancer
4.5. Myxedema Coma

Chapter 5. Global Levothyroxine Sodium (LS) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.1.1. North America LS Market, 2016 – 2026 (US$ Mn)
5.1.2. North America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
5.1.3. North America LS Market, by Country, 2016 – 2026 (US$ Mn)
5.1.3.1. U.S.
5.1.3.2. Canada
5.2. Europe LS Market, 2016 – 2026 (US$ Mn)
5.2.1. Europe LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
5.2.2. Europe LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific LS Market, 2016 – 2026 (US$ Mn)
5.3.1. Asia Pacific LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
5.3.2. Asia Pacific LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America LS Market, 2016 – 2026 (US$ Mn)
5.4.1. Latin America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
5.4.2. Latin America LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa LS Market, 2016 – 2026 (US$ Mn)
5.5.1. Middle East & Africa LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
5.5.2. Middle East & Africa LS Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Mylan Laboratories, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Farmak (Farmak Group N.V.)
6.3. Goldline Laboratories, Inc.
6.4. IBSA Institut Biochimique SA
6.5. Fresenius Kabi USA Llc
6.6. Piramal Critical Care Ltd.
6.7. Cediprof Inc
6.8. King Pharmaceuticals Research And Development Llc
6.9. Abbvie, Inc.
6.10. Takeda Pharmaceutical Company Ltd.
6.11. Merck KGaA
6.12. Jerome Stevens Pharmaceuticals, Inc.
6.13. Pfizer, Inc.
6.14. Teva Pharmaceuticals
6.15. Abbott Laboratories, Inc.
6.16. Sandoz (Novartis International AG)
6.17. Lloyd, Inc.

List of Figures

FIG 1. Levothyroxine Sodium (LS) Market: Research Methodology
FIG 2. LS Market Segmentation
FIG 3. Global LS Market, by Disease Indication, 2017 (US$ Mn)
FIG 4. Global LS Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global LS Market, by Key Players, 2017
FIG 7. Global LS Market for Hypothyroidism Treatment, 2016 – 2026 (US$ Mn)
FIG 8. Global LS Market for Goiter Treatment, 2016 – 2026 (US$ Mn)
FIG 9. Global LS Market for Thyroid Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG 10. Global LS Market for Myxedema Coma, 2016 – 2026 (US$ Mn)
FIG 11. U.S. LS Market, 2016 – 2026 (US$ Mn)
FIG 12. Canada LS Market, 2016 – 2026 (US$ Mn)
FIG 13. U.K. LS Market, 2016 – 2026 (US$ Mn)
FIG 14. Germany LS Market, 2016 – 2026 (US$ Mn)
FIG 15. Rest of Europe LS Market, 2016 – 2026 (US$ Mn)
FIG 16. China LS Market, 2016 – 2026 (US$ Mn)
FIG 17. Japan LS Market, 2016 – 2026 (US$ Mn)
FIG 18. India LS Market, 2016 – 2026 (US$ Mn)
FIG 19. Rest of Asia Pacific LS Market, 2016 – 2026 (US$ Mn)
FIG 20. Brazil LS Market, 2016 – 2026 (US$ Mn)
FIG 21. Mexico LS Market, 2016 – 2026 (US$ Mn)
FIG 22. Rest of Latin America LS Market, 2016 – 2026 (US$ Mn)
FIG 23. GCC LS Market, 2016 – 2026 (US$ Mn)
FIG 24. Rest of Middle East and Africa LS Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Levothyroxine Sodium (LS) Market Portraiture
TABLE 2 Global LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 3 Global LS Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 5 North America LS Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 Europe LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 7 Europe LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Latin America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Middle East and Africa LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East and Africa LS Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 14 Mylan Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Farmak (Farmak Group N.V.): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Goldline Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 IBSA Institut Biochemique SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Fresenius Kabi USA Llc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Piramal Critical Care Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 King Pharmaceuticals Research and Development Llc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Takeda Pharmaceutical Company Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Merck KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Jerome Stevens Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Sandoz (Novertis International AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Lloyd, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Levothyroxine Sodium Market?

The market for Levothyroxine Sodium Market is expected to reach US$ XX Mn by 2026.

What is the Levothyroxine Sodium Market CAGR?

The Levothyroxine Sodium Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Levothyroxine Sodium Market?

The report is forecasted from 2018-2026.

What is the base year considered for Levothyroxine Sodium Market?

The base year of this report is 2017.

Who are the major players in this market?

IBSA Institut Biochimique SA, Fresenius Kabi USA Llc, Piramal Critical Care Ltd., Cediprof, Inc., King Pharmaceuticals Research And Development Llc, Abbvie, Inc., Takeda Pharmaceutical Company Ltd., Merck KGaA, Jerome, Stevens Pharmaceuticals, Inc., Pfizer, Inc. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –